1)Estrogen use and postmenopausal women : a National Institutes of Health Consensus Development Conference. Ann Intern Med 91 : 921-922, 1979
2)Ohmichi M, Tasaka K, Kurachi H, et al : Molecular mechanism of action of selective estrogen receptor modulator in target tissues. Endocrine J 52 : 161-167, 2005
3)加藤茂明 : SERMの組織特異的作用機構の分子機構1 : 36-43, 2005
4)Goldstein SR, Scheele WH, Rajagopalan SK, et al : A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 95 : 95-103, 2000
5)Cauley JA, Norton L, Lippman ME, et al : Continued breast cancer risk reduction in postmenopausal women treated with raloxifene : 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65 : 125-134, 2001
6)Vogel VG : Follow─up of the breast cancer prevention trial and the future of breast cancer prevention efforts. Clin Cancer Res 7 : 4413s-4418s, 2001
7)DeMichele A, Mayer RJ 41st : Annual Meeting of the American Society of Clinical Oncology, Orlando, 2005
8)Shang Y, Brown M : Molecular determinants for the tissue specificity of SERMS. Science 295 : 2465-2468, 2002
9)Lacey JV Jr, Mink PJ, Lubin JH, et al : Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288 : 334-341, 2002
10)Rao BR, Slotman BJ : Endocrine role in ovarian cancer. Endocr Relat Cancer 3 : 309-326, 1996
11)Neven P, Goldstein SR, Ciaccia AV, et al : The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women. Gynecol Oncol 85 : 388-390, 2002